Organon & Co. (NYSE:OGN) Shares Purchased by Blue Trust Inc.

Blue Trust Inc. boosted its holdings in shares of Organon & Co. (NYSE:OGN) by 107.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,599 shares of the company’s stock after purchasing an additional 3,938 shares during the quarter. Blue Trust Inc.’s holdings in Organon & Co. were worth $113,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in OGN. Barclays PLC increased its stake in Organon & Co. by 238.0% during the 3rd quarter. Barclays PLC now owns 119,483 shares of the company’s stock worth $2,285,000 after buying an additional 84,136 shares in the last quarter. Weiss Asset Management LP purchased a new stake in shares of Organon & Co. during the third quarter worth approximately $32,966,000. Cerity Partners LLC raised its stake in Organon & Co. by 94.0% in the 3rd quarter. Cerity Partners LLC now owns 667,340 shares of the company’s stock valued at $12,766,000 after purchasing an additional 323,308 shares during the last quarter. Foundry Partners LLC purchased a new position in Organon & Co. in the 3rd quarter valued at $7,642,000. Finally, Beddow Capital Management Inc. boosted its stake in Organon & Co. by 38.8% during the 3rd quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company’s stock worth $5,867,000 after purchasing an additional 85,775 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Analyst Ratings Changes

Separately, TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $21.33.

Organon & Co. Stock Performance

Shares of OGN stock opened at $14.88 on Friday. The company has a market cap of $3.83 billion, a P/E ratio of 2.95, a PEG ratio of 0.87 and a beta of 0.76. The firm has a fifty day moving average price of $15.39 and a 200 day moving average price of $17.77. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.